HSBC raised the firm’s price target on Biogen to $342 from $339 and keeps a Buy rating on the shares. Biogen’s new growth drivers and cost savings were strong in the quarter, and it is seeing early signs of progress for Leqembi, which is “particularly welcome,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen reports progress on Corporate Responsibility Priorities
- Biogen Reports Progress on Corporate Responsibility Priorities
- Sage Therapeutics price target lowered to $15 from $26 at RBC Capital
- Biogen announces CHMP opinion recommending Tofidence
- Biogen receives positive CHMP opinion for TOFIDENCE